Stadtmauer E A, Cassileth P A, Gale R P
Hematology-Oncology Section, University of Pennsylvania School of Medicine, Philadelphia.
Leuk Res. 1989;13(8):639-50. doi: 10.1016/0145-2126(89)90052-0.
Etoposide, an epipodophyllotoxin structurally related to vincristine, is active in solid tumors. Trials of etoposide in hematologic malignancies, particularly leukemia and lymphoma, were initiated in 1973. Subsequent studies indicate that etoposide, either as a single agent or in combination with other drugs, is active in acute myelogenous leukemia, non-Hodgkin and Hodgkin lymphoma. Etoposide may be effective in acute lymphoblastic leukemia, but it is inactive in chronic myelogenous leukemia. The major toxicity of etoposide is myelosuppression. Non-hematologic toxicity is relatively mild at doses up to 2000 mg/m2. This feature favors its use in high dose regimens such as those employed before bone marrow transplantation. Preliminary studies of etoposide in autologous bone marrow transplantation in lymphoma and Hodgkin disease are promising. Studies of high dose etoposide in combination with other chemotherapeutic agents or in the context of bone marrow transplantation are in progress.
依托泊苷是一种结构上与长春新碱相关的表鬼臼毒素，对实体瘤具有活性。1973年开始了依托泊苷在血液系统恶性肿瘤，特别是白血病和淋巴瘤方面的试验。随后的研究表明，依托泊苷无论是作为单一药物还是与其他药物联合使用，在急性髓性白血病、非霍奇金淋巴瘤和霍奇金淋巴瘤中均具有活性。依托泊苷可能对急性淋巴细胞白血病有效，但对慢性髓性白血病无效。依托泊苷的主要毒性是骨髓抑制。在剂量高达2000mg/m²时，非血液学毒性相对较轻。这一特性有利于其在高剂量方案中的应用，例如在骨髓移植前使用的方案。依托泊苷在淋巴瘤和霍奇金病自体骨髓移植中的初步研究很有前景。高剂量依托泊苷与其他化疗药物联合使用或在骨髓移植背景下的研究正在进行中。
